埃拉戈利克斯 (Elagolix) 是一种比注射性GnRH对手在IVF中抑制排卵的更少侵入性和更便宜的选择
Marco Mouanness1, Zaher Merhi1,2,3
1Reproductive Endocrinology and Infertility, Rejuvenating Fertility Center, New York, NY 10027, USA.
The Journal of clinical endocrinology and metabolism
|March 14, 2024
概括
口服elagolix是一种新的口服性腺激素释放激素 (GnRH) 抗剂,在体外受精 (IVF) 周期中有效抑制排卵. 这种不那么侵入性和更便宜的选择显示了与注射性GnRH抗剂相似的结果.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 在体外受精 (IVF)
- 药理学 药理学是指药理学的学科.
背景情况:
- 可注射性淋巴激素释放激素 (GnRH) 抗剂是IVF排卵抑制的标准,但涉及每日注射和高成本.
- 口服GnRH抗剂,特别是elagolix在IVF中抑制排卵的疗效以前没有被研究过.
研究的目的:
- 为了评估口服elagolix与注射GnRH抗体 (ganirelix/cetrotide) 相比在IVF中控制卵巢过度刺激期间抑制排卵的有效性.
- 评估口服elagolix是否提供可比的素激素 (LH) 抑制和试管婴儿周期结果.
主要方法:
- 追溯队列研究涉及269名接受试管婴儿治疗的患者.
- 患者接受了口服elagolix (50毫克每隔一天) 或每日注射的甘利利克斯/塞特类药物以抑制排卵.
- 测量的主要结果是抑制LH血水平;试管婴儿周期参数也进行了比较.
主要成果:
- 在elagolix和ganirelix/cetrotide组之间,人口和基线特征相似.
- 口服elagolix和注射GnRH抗体都显示出显著且可比的LH水平抑制和雌激素 (E2) 水平的增加.
- 关键的试管婴儿结果,包括卵细胞产量,受精率,胚胎细胞形成,积和子宫内膜厚度,在两组治疗中都相似.
结论:
- 口服elagolix提供了一种更便宜,更少侵入性,更少频繁地用于IVF排卵抑制的替代方案,其疗效与可注射的GnRH抗剂相当.
- 需要进一步的研究来探索口服GnRH抗剂对子宫内膜受体和妊娠结果的影响,特别是在新鲜胚胎移植协议中.
相关概念视频
Birth Control Methods
246
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
246
In Vitro Fertilization
258
In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
258
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Ovarian Cycle
1.2K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.2K
Drugs for Treatment of Diarrhea-Predominant IBS
167
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
167


